• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    NewAmsterdam Pharma (NAMS) Following Q3 Earnings The Undervalued Case Is Back In Focus

    Simply Wall St·11/05/2026 02:52:33
    Listen to the news

    NewAmsterdam Pharma earnings spark fresh focus on Q3 progress

    NewAmsterdam Pharma (NasdaqGM:NAMS) drew fresh attention after reporting third quarter 2026 results, with sales of US$19.16 million and a smaller net loss of US$17.39 million compared with the same period last year.

    The latest figures landed alongside a sharp move in NewAmsterdam Pharma's share price, with the stock up 5.18% on the day of the earnings release. However, it remains down 24.36% over three months and 40.54% year to date on a share price return basis. By contrast, the 3 year total shareholder return of 105.20% and 5 year total shareholder return of 113.14% point to a much stronger longer term story, where recent momentum has faded rather than accelerated.

    Scan how NewAmsterdam Pharma compares with other late stage opportunities by reviewing our curated list of 19 high quality undiscovered gems targeting strong fundamentals that may still be under the radar.

    NewAmsterdam Pharma just rallied on better Q3 numbers, yet the share price still trades well below both analyst targets and intrinsic value estimates. Does that gap signal mispricing, or a fair discount on execution risk?

    Most Popular Narrative: 59% Undervalued

    On the most followed narrative, NewAmsterdam Pharma screens as materially undervalued against a fair value estimate of about $50.92, compared with the last close at $20.93. This puts a lot of weight on how obicetrapib performs in late stage trials.

    The main requirement for success is that PREVAIL delivers a clinically meaningful cardiovascular outcomes benefit that is consistent with the 21% exploratory MACE reduction seen in BROADWAY and the pooled BROADWAY and BROOKLYN data.

    The current valuation implies that NewAmsterdam Pharma already reflects expectations for a successful PREVAIL readout and a commercially meaningful outcomes label, leaving limited room for error but potential upside if the broader cardiometabolic and Alzheimer’s prevention strategy progresses as anticipated.

    See why 2 investors see NewAmsterdam Pharma as 59% undervalued.

    Result: Fair Value of $50.92 (UNDERVALUED)

    Still, the bullish NewAmsterdam Pharma narrative runs into two clear pressure points: PREVAIL outcomes risk and ongoing operating losses that could require further dilution.

    Find out about the key risks to this NewAmsterdam Pharma narrative.

    Next Steps

    Sentiment around NewAmsterdam Pharma is split, which is exactly why it can help to pressure test the assumptions yourself and move quickly while the data is fresh. To see what investors find encouraging about the setup, review the 3 key rewards.

    Looking for more investment ideas beyond NewAmsterdam Pharma?

    Do not stop with one ticker when the broader market may offer opportunities that fit your style even better. Cast a wider net while sentiment is still resetting.